Who are Iterum Therapeutics PLC's main suppliers?

Iterum Therapeutics PLC (ITRM) key suppliers include: Pfizer Inc., Pfizer Inc., PFIZER-INC. View the full supplier network at chainsifter.com/chain/ITRM.

Who are Iterum Therapeutics PLC's major customers?

Iterum Therapeutics PLC (ITRM) key customers include: Myriad Genetics, Inc., Myriad Genetics, Inc., Shionogi & Co., Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Company and 4 more. View the full customer network at chainsifter.com/chain/ITRM.

What sector is Iterum Therapeutics PLC in?

Iterum Therapeutics PLC (ITRM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Iterum Therapeutics PLC Suppliers, Customers & Supply Chain (ITRM)

3Suppliers

9Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Iterum Therapeutics PLC (ITRM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

2Distinct source URLs

7High confidence

0.771Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Iterum Therapeutics PLC Suppliers

Ticker	Name	Confidence	Evidence
PFE	Pfizer Inc.	92%	Reciprocal relationship from PFE graph: Reciprocal relationship from ITRM graph: In November 2015, we and our wholly owned subsidiary, Iterum Therapeutics International Limited, entered into a licens…
PFE	Pfizer Inc.	92%	In November 2015, we and our wholly owned subsidiary, Iterum Therapeutics International Limited, entered into a license agreement with Pfizer (the Pfizer License), pursuant to which we acquired from …
PFIZER-INC	PFIZER-INC	92%	The Company licensed global rights to its novel anti-infective compound, sulopenem, from Pfizer Inc. (Pfizer).

Iterum Therapeutics PLC Customers

Ticker	Name	Confidence	Evidence
MYGN	Myriad Genetics, Inc.	72%	affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for …
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from ITRM graph: affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic un…
SGIOF	Shionogi & Co., Ltd.	72%	Reciprocal relationship from SGIOF graph: Reciprocal relationship from ITRM graph: sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating…
SGIOF	Shionogi & Co., Ltd.	72%	sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. Changes in and uncertainty surrounding trade policy, includin…
BMY	Bristol-Myers Squibb Company	62%	Reciprocal relationship from BMY graph: Reciprocal relationship from ITRM graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ITRM graph: Reciprocal relationship from BMY grap…
CHEVRON-U-S-A-INC	CHEVRON-U-S-A-INC	62%	d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our…
CO-LTD	CO-LTD	62%	sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. Changes in and uncertainty surrounding trade policy, includin…
CORNER-POST-INC	CORNER-POST-INC	62%	d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our…
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	62%	d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our…

Iterum Therapeutics PLC Debt Obligations

Instrument	Description	Confidence	Evidence
ITRM-DEBT-10385	Warrants outstanding: 25333	90%	xbrl warrant detail from xbrl 2025-04-28.
ITRM-DEBT-10386	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
ITRM-DEBT	Debt stack $33.7M	90%	Market cache reports total debt of $33.7M.

Iterum Therapeutics PLC Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Iterum Therapeutics PLC.

Iterum Therapeutics PLC Ownership

Holder	Name	Confidence	Evidence
ITRM-OWNER-HRT-FINANCIAL-LP	HRT FINANCIAL LP	90%	13F overlay lists HRT FINANCIAL LP as top holder; 18 tracked holders.

Iterum Therapeutics PLC Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IMNM	Immunome, Inc.	100.00	2
DNLI	Denali Therapeutics Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
SUPN	Supernus Pharmaceuticals, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	1	['customer']
PSNL	Personalis, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
JANX	Janux Therapeutics, Inc.	100.00	2

Iterum Therapeutics PLC Supply Chain